L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

Inclusion Criteria: * Biopsy proven adenocarcinoma of the breast * Received at least one prior taxane-containing chemotherapy regimen which resulted in persistent taxane-induced peripheral neuropathy * Anticipated survival of at least 6 months * Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1, or 2 * The patient must have screening laboratory: Transaminases\<2.5 x upper limit of normal; total bilirubin \<2.0; creatinine \<1.5 * Neuropathy onset from taxane administration no more than 18 months from date enrolled in trial * Willingness to adhere to supplemental regimen of l-glutamine 10,000mg taken orally twice daily, with one potential dose escalation to 10,000mg taken orally three times daily. * Grade I-III sensory peripheral neuropathy related to prior taxane use as assessed by their treating oncologist at Eastern Regional Medical Center * Able to give informed consent for protocol participation Exclusion Criteria: * Participants are not able to understand or provide written informed consent. * The research team deems that the participant may not be able to follow the study protocol. * Current diagnosis of bipolar disorder or other manic state * Prior use of l-glutamine for prevention or empirical treatment of taxane-induced sensory peripheral neuropathy * Prior treatment with a platinum chemotherapy * Concurrent use of physical therapy interventions such as the 'Rebuilder', chiropractic care, acupuncture, or other modalities specifically targeting peripheral neuropathy * Concomitant use of nutraceutical supplements which may mitigate symptoms of taxane-induced peripheral neuropathy including B-Complex vitamins, alpha-lipoic acid, vitamin E, acetyl-l-carnitine, intramuscular B12 injections, fish oil, etc… during study * Renal insufficiency : serum creatinine of \>1.5 mg /dl * Hepatic insufficiency: transaminases \> 2.5 x upper limit of normal due to isolated reports of possible hepatic encephalopathy * New prescription or dose adjustment of current medication for the treatment of peripheral neuropathy such as gabapentin or Lyrica within the past 30 days. * Pre-existing sensory peripheral neuropathy from other comorbid conditions such as diabetes or alcoholism * Current serious infection or other serious medical condition * Currently active second malignancy other than nonmelanatous skin cancer or carcinoma in situ of the cervix * Pregnant or lactating female (pre-menopausal females will undergo pregnancy test prior to administration of protocol drugs throughout treatment cycles during this study) * Acetaminophen use exceeding 2 g per day-includes use of acetaminophen-containing pain medications such as Percocet.